SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a new AI chip deal with OpenAI, sparking optimism about its competitive position against Nvidia. The community is discussing the potential impact on AMD's stock price, with some highlighting the deal's structure and future revenue possibilities. This news has triggered a surge in investor interest and bullish sentiment around AMD's role in the expanding AI infrastructure market.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences is trending due to FDA granting Breakthrough Therapy Designation for their drug targeting a rare disease, Sanfilippo syndrome type B, leading to a massive short squeeze. The community is discussing potential buyouts and comparing it to similar explosive moves in other low-float stocks, while also debating entry and exit points amidst the extreme volatility. Some traders believe the stock could still run much higher due to its small float and the potential market size, while others warn of an inevitable crash.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to multi-year AI cloud contracts for NVIDIA Blackwell GPUs, sparking excitement about the company's pivot towards AI infrastructure. The community is discussing the potential for significant growth and comparing IREN's valuation to its peers, with some speculating on future deals and price targets amid the AI infrastructure boom.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as community members discuss its potential following a large contract announcement, while also debating the reasons behind the stock's recent price action. Some are citing the company's AI capabilities and undervaluing, while others point to market manipulation and await further news to validate their positions. Community members are referencing upcoming earnings as a catalyst.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Siyata Mobile Inc

Siyata Mobile is trending as it finalizes its merger with Core Gaming, anticipated to trade under the ticker $CHAI next week, although some confusion exists around the exact start date. The community is actively discussing the reverse stock split associated with the merger, potential share lock-up periods, and the future valuation of the combined entity, with some expecting a squeeze. Discussion is centered around the potential of $CHAI in the AI gaming sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending downwards following reports of an SEC probe into its data collection practices, sparking debate among investors about the potential impact and severity of the investigation. The community is actively discussing whether this is an overblown reaction fueled by short-sellers or a legitimate concern that could clip the company's growth. Despite strong fundamentals, the probe adds uncertainty to AppLovin's outlook as it heads into its upcoming earnings.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors discuss its potential in the quantum computing sector, drawing comparisons to Nvidia and fueling speculation about a short squeeze. The community is weighing the company's long-term prospects against valuation concerns and potential dilution. Some traders highlight the potential for significant gains while others point to risks and an impending correction.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid speculation regarding a potential U.S. government investment in the company's Greenland rare earth project, though some sources deny active consideration. Community discussions revolve around the validity of conflicting reports and the potential for a short squeeze, given the stock's volatility and existing short interest. The company's assets and the strategic importance of rare earth minerals are also key talking points.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a partnership with Tesla, sparked by a teaser video and cryptic posts, leading to significant intraday call buying. The community is actively discussing potential price targets and the likelihood of a short squeeze, though some caution that the surge is purely hype. Broader context includes Archer's position in the competitive eVTOL sector and upcoming catalysts that may affect future momentum.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending as chatter increases around a potential crypto launch and speculation about inclusion in the S&P 500. Community members are actively discussing short squeeze potential, technical indicators, and comparing SOFI's valuation and prospects to other fintech companies like HOOD. Some investors believe SOFI is undervalued, citing its growth potential and strategic initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the companys...

Shares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company reported promising trial data for its experimental drug veligrotug, aimed at treating chronic thyroid eye disease (TED).Viridian announced that in a late-stage trial, 56% of veligrotug-treated patients experienced a reduction in proptosis, or abnormal eye bulging, achieving a mean reduction of 2.34 mm.&nbsp;Additionally, 56% of participants reported reduced diplopia, or double vision, with 32% achieving complete resolution.&nbsp;The trial also delivered a 2.9-point mean reduction in inflammatory signs and symptoms from baseline, with the drug being well-tolerated and associated with only mild adverse events.Thyroid eye disease, which causes inflammation and damage to the tissues surrounding the eye, affects an estimated 90 to 300 people per 100,000 in the U.S.Viridian confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VRDN_sentiment_and_message_volume_Dec_16_bd76e824a8.png" alt="VRDN sentiment and message volume Dec 16.png" width="1318" height="324"><figcaption>VRDN sentiment and message volume Dec 16 as of 9:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Viridian’s stock turned ‘extremely bullish’, with the ticker entering the platform’s top 15 trending symbols.&nbsp;One user described the news as making the stock a “long-term hold for me.”&nbsp;Another hinted that veligrotug could offer better returns for Viridian than Tepezza, an FDA-approved TED drug marketed by Horizon Therapeutics, which was acquired by Amgen in October 2023 for $27.8 billion.Viridian also expressed optimism about its VRDN-003 program, an IGF-1R antibody in development for TED.&nbsp;The company said the combined results from the THRIVE and THRIVE-2 trials bolster confidence that VRDN-003 will deliver positive topline data by the first half of 2026, enabling a BLA submission in the second half of the same year.&nbsp;Still, Viridian stock remains down about 20% year-to-date, as of its last close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.

Equity

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.


Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive...

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent...

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the company or Viridian), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

Analyst Expectations For Viridian Therapeutics's Future

Latest Ratings for VRDN
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkInitiates Coverage OnOutperform Nov 2021JMP SecuritiesMaintainsMarket Outperform...

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$20.83
Prev Close	$21.65
Open	$21.70
Dividend Yield	0.00%
50-Day Moving Average	$18.81
Beta	1.02
Avg. Volume	766,172.81
PE Ratio	-4.88

52-Week High	$27.20
52-Week Low	$9.90
Market Capitalization	$1.7B
EPS (Annual)	-$3.07
Price to Book	5.21
Revenue Per Employee	$2,111.89
Enterprise Value/EBITDA	N/A

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VRDN News

VRDN Viridian Therapeutics Inc